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The COVID-19 pandemic has devastated individuals, families, and institutions throughout the world. Despite the
breakneck speed of vaccine development, the human population remains at risk of further devastation. The
decision to not become vaccinated, the protracted rollout of available vaccine, vaccine failure, mutational forms
of the SARS virus, which may exhibit mounting resistance to our molecular strike at only one form of the viral
family, and the rapid ability of the virus(es) to hitch a ride on our global transportation systems, means that we
are will likely continue to confront an invisible, yet devastating foe. The enemy targets one of our human
physiology’s most important and vulnerable life-preserving body tissues, our broncho-alveolar gas exchange
apparatus.
Notwithstanding the fear and the fury of this microbe’s potential to raise existential questions across the entire
spectrum of human endeavor, the application of an early treatment intervention initiative may represent a
crucial tool in our defensive strategy. This strategy is driven by evidence-based medical practice principles, those
not likely to become antiquated, given the molecular diversity and mutational evolution of this very clever
“world traveler”.

☆
This paper, tables, figures and recommendations are meant to be followed in conjunction with the advice of a medical professional such as your Primary or
Principal Care Provider. Although the recommendations are sound, there may be underlying reasons why a specific patient SHOULD NOT follow all of the rec
ommendations. Please consult your Medical Provider for specific instructions and guidance.
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1. Introduction

diagnostic confirmation, or as early as possible, and irrespective of
symptom magnitude.
Symptom severity has been demonstrated to poorly correlate (espe
cially when considering individual patients, which is how we best pro
vide CARE for them, individually, one at a time) with propensity to
transition to severe disease. It is not uncommon to appreciate a
mismatch between clinical semiology and the underlying histopatho
logical burden of disease. This highly salient aspect of COVID-19 is not
dissimilar to other conditions whereby the presence of a mild clinical
disease phenotype does NOT militate against the simultaneous presence
of occult disease activity. In fact, in a disease such as multiple sclerosis, a
‘clinico-radiologic-paradox’, provides instructive principles which un
derscore the powerful prognostic predictability for future severity of
disability, contingent upon the dissemination and volumetric burden of
central nervous system lesions, despite the absence of significant clinical
correlation at the time of magnetic resonance imaging (MRI). Similarly,
considerable and constitutively recalcitrant targeting, injury, and even
obliteration of our bronchoalveolar gas-exchange apparatus, can pro
gressively advance in a mildly affected COVID-19 patient (even in those
completely asymptomatic), until a critical threshold of injury is excee
ded such that the patient then exhibits the highly salient and most
treatment refractory clinical characteristics, which are the cardinal
hallmarks of severe COVID-19, the phase of this disease state which must
be actively prevented in order to provide the best chance for optimizing
recovery, limiting tissue and organ damage, thereby extending life and
the quality of it.
Our ‘front-line’ healthcare alliance desperately need a carefully
assembled, and coherently codified, multidisciplinary, remissionexacting treatment strategy to prevent transition to severe disease.
Such a tool could serve to literally decouple the vast out-patient popu
lation of COVID-19 patients as the primary driving source for emergency
and acute care service demands, which far exceeds the resources
available, even within and across the most advanced, expansive, expe
rienced and well-endowed healthcare systems and infrastructures in the
world. Providing a pragmatic, evidence-based, and out-patient treat
ment strategy, predicated upon established medical practice principles,
and commensurate with the realistic objectives, and the much needed
confidence to advance our capabilities from those of community ascer
tainment, diagnostic confirmation, adoption of public health and home
quarantine, to a bona fide disease-modifying strategy aimed at abol
ishing COVID-19, and neutralizing its pathoetiologic agent, the SARSCoV-2 virus.

Never before has the human family shared a more compelling and
existential challenge from which to acknowledge our common plight,
rather than our differences. Only through the establishment and mutual
endorsement and enforcement of universal public health principles,
collaborative research on a global scale, and universal preparedness to
act decisively with early and strategically formulated interventions, can
we hope to stay ahead of this most formidable foe [1,2].
Supported by long-established standards of care protocols, as well as
randomized controlled trials aimed to either confirm or refute
hypothesis-driven therapeutic questions on the efficacy of novel agents
identified through innovations in discovery, we are on the brink of
ushering in a literal Renaissance of modern medicine. The era’s over
arching goal shall be to establish the most sophisticated attempt to date,
utilizing discrete knowledge of human heterogeneity, for the identifi
cation of effective treatments for even a single patient, the era of Pre
cision CARE. Until then, we share herein a protocol for the early
treatment of mild and moderate COVID-19, the purpose of which is to
prevent the transition to severe disease.
1.1. Omission of an early treatment strategic initiative fueled the hospital
crisis
The circumstances of the COVID-19 crisis created many formidably
complex challenges in clinical trial design and execution. Nowhere has
such complexity been more limiting than in the outpatient investigation
of infected patients characterized as having mild to moderate disease,
and who have been summarily sent home without education, coun
seling, monitoring recommendations, nor with any treatment interven
tion whatsoever. This in part is due to the overwhelming numbers of
patients flooding our hospitals and point of care services, but also
because our global healthcare system’s most precious asset, our ‘frontline-people’ (composed of physicians, nurses, nurse practitioners, physician
assistants, and their support staff across the spectrum of emergency and acute
care medical services), are tired and have been completely overwhelmed.
Further, ‘our people’ have not been equipped with a systematic,
educational, and corresponding out-patient multidisciplinary treatment
strategy for mild and moderate COVID-19, with the specific aim of
preventing the transition to severe disease, an achivement of monu
mental significance for both those we serve, and for those with the un
precedented fiduciary responsibilities who do the ‘serving’.
Notwithstanding the preeminent importance of the expanding global
vaccine initiative, and achieving the highly anticipated goal of herd
immunity, in the interim, we are recognizing disseminated and
dangerously expanding spikes in new cases of COVID-19. Mid-April
2021 has the highest incident rates of the pandemic since the inception.
This ominous observation, along with evidence of new cases emerging
among vaccinated patients (as well as those who remain steadfast in
their opposition to active immunization, at least via vaccination, a su
perior method of actively acquired immunity when compared to
developing COVID-19 via infection with the SARS-CoV-2 etiologic
agent) provides the most compelling justification to date to offer COVID19 patients specific treatment recommendations at the time of

1.2. The telemedicine transformation: limitations and opportunities
The near cessation of outpatient clinic medicine, and the trans
formation to virtual telemedicine resulted in a critical disconnection
between providers and patients, and the framework of systematic
methods for translating clinical history and the performance of the
directed examination into the corresponding formulation of diagnostic
and treatment plans. Alternately, the rapid availability and adoption of
the telemedicine platform did allow us to use a convenience sample of
consecutive patients seeking our help with COVID-19 management.
Disseminating information about their experience to family, friends, and
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colleagues has led to a nearly geometric application of our current
treatment protocol, outlined in this paper, to COVID-19 patients
throughout the country and globally.
Our willingness to provide counsel and specific treatment recom
mendations, based upon established and evidence-based, medical
practice principles, has compelled us to share information germane to
already established standards of care. The number of lives potentially
saved with this protocol, as well as those protected from the potential of
residual deficits we now recognize to be plaguing many patients, “the
long-haulers syndrome”, grows as we target those who were designated as
having mild to moderate disease or even asymptomatic individuals.

and alveolar loss accumulates.
2.2. Life sustaining oxygen: supply:demand bioenergetics
What part of us does NOT need to utilize oxygen? Insufficient oxygen
delivery compromises mechanisms in our physiology which aim to
match the supply of energy currency with that of tissue and organ
functional demands. Most crucially, the amounts of energy currency
being made (i.e. adenosine triphosphate (ATP)) and its energy currency
colleagues, flavin adenine dinucleotide (FAD), and nicotinamide adenine
dinucleotide (NAD), all require oxygen to run the electron transport
chain in our cellular mitochondria, and may become wholly inadequate
to maintain the high efficiency state of the health, wellness, and quality
of life that is inextricably coupled and dependent upon the integrity and
high fidelity processes which characterize the biochemistry of human
intermediary metabolism.

2. Outcome observations of early treatment intervention
At the time of the completion of this manuscript for submission, the
lead author treated more than 125 patients with confirmed COVID-19
following the protocol described in this paper. In conjunction with es
timates from colleagues, the number of patients treated with the
enclosed protocol exceeds 1000. To date, of those who followed this
protocol, we are unaware of a single COVID-19-related death, or of a
single patient who has required pressure ventilation in an intensive care
unit. Further, the vast majority of those treated with the regimen have
exhibited a stereotypic defervescence of symptoms and a marked and
durable recovery within 4–10 days with only an occasional patient
reporting features suggestive of “long-hauler’s” syndrome.
We must replicate our observations in the context of a rigorously
controlled trial, with methodology aimed to also expose confounding
influences that always accompany such investigations. Our observations
from a convenience sample are not, however, irrelevant. This is espe
cially true given that we base our recommendations upon evidence that
supports the employment of pragmatic, effective, and timely treatment
recommendations, just as we would for many other conditions. The
regimen detailed herein crosses the domains of in-home monitoring,
application of nutritional principles, pulmonary hygiene, as well as the
intervention with therapeutic agents aimed at attenuating the inflam
matory crisis in the lungs while seeking to maintain both ventilation and
perfusion characteristics, the physiologic coupling of which defines our
life-sustaining gas exchange apparatus.

2.3. Consequences of delayed treatment intervention
If all who are infected are urgently treated, we not only attenuate the
Prolific Activation of a Network Immune Inflammatory Crisis (‘PANIC’)
Attack of inflammation, but also abort viral replication [2]. This halt in
replication abolishes downstream tissue injury mechanisms at both ends
of the COVID syndrome. These mechanisms include the parochial trig
gering of ‘PANIC’, where we can least recover from the inflammatory
crisis, the broncho-alveolar gas exchange units of the most remote rea
ches of our lung anatomy and physiology. Additionally, the high-jacking
of our alveolar epithelial molecular machinery for its own self-serving
purposes causes an additional bystander effect that is the irreversible
damage and obliteration of this most precious asset of gas exchange,
which cannot be replaced.
The prevention, as well as the reversing of the high-jacking of our
alveolar epithelial cell molecular machinery for purposes of the SARSCoV-2 viral replication, represents another major goal of COVID-19
treatment. Halting replication itself reduces the inflammatory ignition
switch that foments site activation of exuberant inflammation, while
releasing factors (e.g. C3a and C5a; anaphylatoxins and chemotaxins)
promote the redistribution of peripheral immune effector cells,
recruiting them to the site of primary infection, the broncho-alveolar
units. Upon the arrival of the peripheral immune effector cells to the
primary site of infection, the bronco-alveolar units, the effector cells
release free radicals, super oxides, and other injurious agents, which all
serve to intensify and expand the injury cascades.
Less viral presence also means a reduced likelihood of viral segment
integration within the alveolar epithelium (as so-called “syncytia”), with
SPIKE protein ‘dangled’ into the alveolus, potentially generating anti
body locally from our own B cells. This may sound like a good thing? It is
not! Such locally generated antibodies against SPIKE protein on the SARSCoV-2 virus expressed upon our alveolar epithelium ignites the terminal
complement cascade, specifically the C5-convertase. This in turn promotes
the assembly of proteins derivative of the C5, C6, C7, and C8 pathways
to construct the terminal and most injurious effector mechanism of the
entire complement system, the membrane attack complex (MAC).
In the case of COVID-19, MAC assembly upon our alveolar epithe
lium is then primed for the final “kill-shot”. Specifically, the MAC ar
chitecture includes a centrally localized channel which facilitates the
passage of the terminal complement protein C9 from the opening
orientation directly toward the alveolar space. The MAC architecture
serves as a direct line of sight for the bullet-like action of C9 upon
reaching the terminus of the MAC adhered to the epithelial surface.

2.1. Application of established medical practice principles
With the pandemic and its ultrarapid dissemination of infectivity
throughout the world, our current submission is meant to be a contri
bution to the cause of reminding clinicians to reach back into the toolbox
of their general medical training and never forget that there are many such
tools available to fulfill our first commitment to each and every patient that
we evaluate. The first commitment is to CARE, and CARE enough to
employ strategies that were somehow passed over during the ongoing
pandemic. Quite often, these strategies were opaquely overshadowed by
the politicization of the world’s medical response to this most unparal
leled threat to the health and wellness of the human family, and as such,
of all the nations of the world.
Having an early treatment protocol for all who test positive, irre
spective of symptom magnitude, is smart medicine. Why? Symptoms do
not necessarily reflect the underlying damage happening; a process we
now know is constitutive, even in those asymptomatic. Why care if you
don’t have symptoms? The answer is simple; you can change tracks to
more severe disease and still have morbidity and mortality, and most
importantly, the damage already sustained may not appear relevant
now, but may be relevant later, once critical thresholds in tissue damage
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Upon its arrival, C9 then penetrates the alveolar cell membrane,
inflicting an irreversible breach in the integrity of the cell’s barrier and
physiologic dividing line, crucial for maintaining innumerable pro
cesses, including those that sustain the life and viability of these cells.
The “kill-shot” mechanism culminates in osmotic shock, completing
what we now designate as complement-dependent cytotoxicity (CDC).
What then follows is damage commensurate with the transition to severe
disease and the heightened risk of alveolar obliteration.

beyond our capability to nurse them back to health, or even to save their
lives.
2.5. Specific aims of our paper and accompanying YouTube video
This paper is our attempt to focus precisely upon strategies that have
successfully ‘left-shifted’ patients toward ultimate recovery, and away
from the potential ‘right-shifting’ to severe disease, and the corre
sponding escalation in morbidity and mortality associated with it.
We begin by advancing a number of ‘Imagine’ statements, specif
ically focused upon the marked mitigation of this pandemic and its ef
fects upon people, families, communities, and institutions. We then
detail a specific, albeit not dogmatic, regimen which addresses a di
versity of semiologic factors associated with COVID-19, and which can
be remedied with the employment of established practice principles and
their systematic implementation, given that all that we proscribe, de
vices, techniques, nutritional agents, and prescription medications, are
all generic and widely available throughout the world [3–110].
This paper is intended to showcase our protocol in conjunction with
medical illustrations to be utilized for purposes of organization, and for
counseling each of our individual patients and their families. Similarly,
we provide a highly detailed figure, along with a table of detailed leg
ends such that the pathophysiologic underpinnings of COVID-19 can be
parsed and individually addressed in terms of mitigating or even
achieving the remission exacting effects of our proposed interventions
[111–116].
This paper is accompanied by a video, published here (click on
thumbnail) and on YouTube (https://thefrohmanfoundation.org/o
utpatient-covid-19-treatment-to-prevent-severe-disease/), that shall be
released in synchrony with the publication of this manuscript. The
multimedia architecture of the video is intended to inform, educate,
counsel, inspire, and to build confidence both among those infected, as
well as their family members, and their CARE provider alliances.

2.4. Dividends of early/earliest treatment intervention for COVID-19
Now imagine if all patients were treated at the time of diagnosis,
when COVID-19 is at its mildest to moderate stages, with interventions
aimed at multiple mechanisms that when uncoupled, we have our best
chance to protect the lung, monitor the disease process at home, and
remain in touch with care providers in order to provide guidance, course
changes, and always with the default of hospitalization should the
condition warrant closer observation and/or intensification of the
treatment plans.
This is a highly unusual paper. Why? Its principal purpose is to un
derscore the prospects and possibilities of controlling the most dangerous
aspects of the COVID-19 pandemic before it begins. Imagine if the world
recognized that by having the advents of public health practices,
coupled with an effective out-patient treatment regimen, we could
prevent hospitalizations and death, while our vaccination programs
come to fruition and herd immunity is ultimately achieved.
We absolutely believe this can be achieved if enough of our medical
community and patient population (essentially everyone) accepts the
premise of the hypothesis that we put forth. However, we must be
prepared for new variants, and to learn from the painful and cataclysmic
lessons of the current pandemic. One glaring observational lesson is that
the medical community became completely paralyzed by the increasing
and inevitable onslaught of severe illness, ultimately exceeding our
available resources.

(Click here)

One very painful outcome of this past year of the pandemic experi
ence is that there has been almost a complete lack of management of
those with mild and moderate disease, as well as those wholly asymp
tomatic. Unfortunately, it is during this initial time, the initial assess
ment where patients have been summarily told to ‘go home and not
return until you are more sick’, that may represent a time when they are

It is our hope that by bringing this real-world experience to light, it
shall broadly illuminate for all to see, a systematic strategy capable of
solving the complex riddle of the SARS-CoV-2 agent, and its clinical
manifestations as COVID-19. We take a broader view of the inception of
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the illness, exploit the vast toolbox of established medical, health, and
wellness capabilities that can be wielded with predictable effects,
including the ability to abort the infection, and thereby abolish the
mechanisms responsible for the consequences of this infection.

Supplementary data to this article can be found online at https://doi.
org/10.1016/j.jns.2021.117463.
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The reports of new mutations, in conjunction with spikes of the
illness being disseminated throughout the world, suggest that this paper
offers a timely plan to mitigate the illness and prevent the transition to
severe disease.
This monitoring and treatment protocol recognizes CARE pathways
addressing each of the early mechanisms and manifestations of this
illness, while assembling a concerted attack directly upon the culprit, as
well as applying a treatment strategy which finally is focused upon the
most relevant constellation of treatable facets of this dangerous, com
plex, and clever microbial agent [3–116].
From the start, we have possessed the tools to ‘checkmate’ this
challenger, despite it targeting of one of our body’s most vulnerable and
life-sustaining circuitries. Even at the most remote reaches of our lung
physiology, employment of site-selective inhalational therapies, in
conjunction with nutritional support measures, pulmonary hygiene, and
respiratory muscle training, we can begin to provide a path forward by
which to prevent symptom worsening and possibly prevent hospitali
zation, while learning lessons that shall prepare us for future challenges
that shall no doubt be forthcoming.
Herein the time is right to now begin by asking you, the reader, to be
open minded enough to consider the “IMAGINE” statements that follow;
inspired by John Lennon’s 1971 verse from his raison d’être.
IMAGINE
“You may say I’m a dreamer
But I’m not the only one
I hope someday you’ll join us
And the world will be as one”
John Lennon, October 11, 1971
Imagine
Imagine
Imagine

Imagine
Imagine
Imagine
Imagine

Imagine

Imagine
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If we could treat patients with COVID-19 at the beginning, when most
only have mild to moderate disease, thereby preventing severe disease.
If the treatment were based on evidenced-based medical principles and
such a regimen were completely detailed right here for you, your family,
and your healthcare provider.
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and together we can lives.
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Fig. 1. All steps are taken for a total of 10 days.
[Numbers Correspond to those in Fig. 1]
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Fig. 1. (continued).
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Mucus Clearance & Pulmonary Hygiene
9. Guaifenesin

To promote liquification of mucus for subsequent mobilization out of the
peripheral bronchopulmonary tree, we recommend using guaifenesin
(available over the counter in most countries) twice daily at 1200 mg,
extended-release formulation.
If the cough is excessive or fatiguing, then guaifenesin + dextromethorphan
(the latter, a cough suppressant, can also attenuate adenosine mediated
headaches) is indicated.
Thick mucus formation can become organized in the distal bronchioles and
compromise local and then general ventilation characteristics, ultimately
affecting gas-exchange at the alveoli apparatus. [38-52]

10. Postural Percussion

Mobilization (expectoration) of distal mucus (in those with no cough, nonproductive cough, and with productive cough) by liquefying (following step 9,
above). Follow by either manual postural percussion or use of a percussion
vibratory instrument on the back, to dislodge mucus in the upper and lower
lobes (right and left), and apply similar percussion to the right middle lobe, also
known as the lingular lobe.
This is key, as the right middle lobe is the one at greatest risk of
consolidation and infection, along with atelectasis (a partial or complete
collapse of the lung).
Right middle lobe pulmonary hygiene (i.e. percussion and expectoration) is
best achieved by having the patient raise their right arm and percuss from
the front approximately under the breast between the 4th or 6th intercostal
spaces. [53-55]

11. Pulmonary
Conditioning and
12. Respiratory Muscle
Training

Performance of pulmonary exercises promotes normalizing pulmonary
functioning via improved conditioning. 10-20 breaths of inspiration and
expiration with The Breather (a respiratory muscle trainer which can be purchased
online, as well as other devices such as incentive spirometry device), three times
daily. Begin at setting #1; each day see if the patient can advance by one setting
until arriving at the top setting (e.g. with the highest resistance to inspiration and
expiration). [56-60]

Fig. 1. (continued).
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Advance Therapy # 1
13. L-Albuterol &
Budesonide

We recommend inhalational L-albuterol to facilitate improved ventilation
and delivery of medication to the distal bronchopulmonary tree. L-albuterol
has the active “R” isomer of the molecule and serves to relax bronchial smooth
muscle, and is more lung selective than the racemic form (R & D isomers).
Albuterol is a beta-2 adrenergic agonist and serves to relax bronchiole smooth
muscle. Additionally, via its interaction with beta-receptors on lung mononuclear
cells (especially macrophages, T- and B-lymphocytes), it promotes the escalation
in intracellular cAMP, and thereby the transition of mononuclear cells from proinflammatory to modulated and even to a regulatory cell phenotype. This
mitigates the “Prolific Activation of a Network Immune Inflammatory Crisis”
(PANIC), the principal mechanisms of COVID-19 associated with tissue damage
of the lungs. [61-65]
We recommend 2 puffs twice daily, along with 2 puffs of a budesonide
inhaler (Pulmicort) administered 5 minutes after taking L-albuterol inhaler
therapy, to provide some time for bronchial smooth muscle relaxation.
Administration of L-albuterol improves ventilatory characteristics for the
site-selective delivery of the inhalational steroid budesonide into the distal
broncho-alveolar region of the most distal bronchopulmonary tree. This
subsequently acts to coordinate a constellation of steroid-mediated antiinflammatory actions, also serving to mitigate the effects of COVID-19-associated
inflammatory activity. After administration of the two inhalational puffs of Lalbuterol, followed by the two puffs of budesonide, we recommend that the patient
gargle with water x 2 and spit, to avoid the development of thrush. [66-67]

14. Baby Aspirin

Unless formal anticoagulation is indicated, (per guidelines contingent upon DDimer levels), we recommend 1 baby aspirin daily (81 mg) for purposes of
reducing clot and sludging via platelet inhibition (unless aspirin in the patient
is contraindicated). [68-77]

15. Avoid Overhydration

Avoid overhydrating because increased protein-rich fluid can accumulate in
the distal bronchopulmonary tree, which can increase the distance between
the alveolar epithelium and the pulmonary vascular capillary bed endothelium,
thereby compromising the gas exchange apparatus (as demonstrated in the
FACCT TRIAL). If your patient is dehydrated (e.g. from diarrhea), then fluid
reconstitution and potentially potassium repletion may need to be
considered. [78-82]

16. Proning

Lie prone (positioned on your stomach) during sleep (or perhaps 2/3 of
sleep time prone, the other 1/3 supine).
This improves the oxygen saturation of arterial red blood cell hemoglobin
(as demonstrated in the PROSERVA TRIAL). [83-87]
Fig. 1. (continued).
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Advance Therapy # 2

Fig. 1. (continued).
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Fig. 2. Pathophysiology of severe COVID-19 from mild/moderate COVID-19 and the mechanistic treatment for its prevention.

General Architecture
Legend
The color-encased
boxes are utilized for
purposes of:

Overall, this figure is dichotomized by characterizing the features of mild
and moderate COVID-19 and the interventions that comprise our regimen
to prevent progression to severe disease.
Defining a problem (RED box)
Potential complications from the problem (DOTTED RED box)
Proscribed intervention (GREEN box)
Rationale for each intervention (ORANGE box)

Mucus Inspissation
Potentially mixed
with bacterial flora

Mucus Obstruction
of the distal
bronchopulmonary
tree

To prevent the organization of complex inspissated mucus with bacterial
flora in the distal bronchopulmonary tree, potentially serving to “endocast”
the bronchoalveolar anatomy responsible for ventilation and perfusion
characteristics germane to high-fidelity gas exchange.
The SARS-CoV-2 virus, which causes COVID-19, principally does so by
targeting our most vulnerable lung anatomy, the bronchoalveolar
terminals where high-fidelity gas exchange occurs, representing the
entire body’s supply of oxyhemoglobin and its delivery via
cardiopulmonary physiology [2, 112].
To maintain such constant and uninterrupted gas exchange, both
ventilation and pulmonary arterial perfusion must be commensurate with
threshold states that guarantee the reliable delivery of oxygen to the
pulmonary arterial capillary network, while the lung parenchyma
simultaneously expels carbon dioxide by reverse expiratory flow,
oscillating with the inspiration of fresh air whose composition is 21% O2.
Oxygenated pulmonary venous return to the left heart is then prepared to
deliver cardiac output via the left ventricular systolic pump and its ejection
fraction of blood in to and out of the aortic root.
The mobilization of dangerous mucus organization in the distal
bronchioles is achieved with a combination of:
1. Liquification via 800-1200mg of oral twice daily guaifenesin,
2. Excessive cough, which can be counteracted by the use of
guaifenesin with dextromethorphan
3. Manual percussion of the upper and lower lung lobes from the
back and anterior percussion of the right middle lobe, which can
serve to mobilize and ultimately expectorate the mucus burden in
the distal lung fields.
4. Percussion and mucus expectoration, which is more efficiently
achieved by utilizing a vibratory “gun,” making this part of
pulmonary hygiene less cumbersome and exhausting for the
assistant, partner, or family member.
5. Special attention given to the right middle lung lobe, approaching
anteriorly (between the 4th-6th intercostal spaces, with the breast
lifted in those with abundant breast tissue) Remember that the
right middle lobe is most predisposed to the development of
pneumonic consolidation (i.e. pneumonia and pneumonitis), as
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This “Necessary Drug”, as designated by the World Health Organization
(WHO), exerts broad pleiotropic mechanisms. These mechanisms
include:
x

pharmacologic duality as both a folate analog, as well as folate
antagonist,

x

cell cycle S-phase inhibitor,

x

inhibition of DNA and RNA base synthesis for both purines and
pyrimidines, thereby exerting a powerful inhibition of viral
replication (including that of SARS-CoV-2)

x

marked attenuation of cytokine release syndromes,

x

modulation of adenosine mediated anti-inflammatory
mechanisms,

x

inhibition of NFNB, and

x

promotion of the production of tissue inhibitors of
metalloproteinases [TIMPS], modulation of JAK/STAT signaling
platforms, modulation of reactive oxygen species, and inhibition
of the binding of HMGB1 to RAGE, or indirectly interfering with
this interaction via inhibition of the cytokine production of TNF-D,
IL-1, IL-6, and IL-8). [2]

There does come a time when the above interventions are not sufficient
to avoid the “right-shifting” of the patient from mild/moderate COVID-19
into severe disease. Such circumstances necessitate hospital admission
for:
1. Close observation
2. Augmentation of oxygen support (e.g. 1-4 L of O2 by nasal
cannula

Hospital Admission

3. Expanded investigations to ascertain the severity of metabolic
and hematologic derangements (Ferritin, hsCRP, D-Dimer),
presence of concomitant infection (including secondary
pneumonia, if bacterial suspected prompting treatment with IV
antibiotics), and CT assessment of the lung, to stage the severity
and burden of injury to the lung parenchyma. Further, cardiac
investigations are increasingly being performed given increasing
evidence that COVID-19 can affect the heart, predisposing
patients to markedly increased morbidity and mortality.
To diagnostically and therapeutically address extra-pulmonary
organ pathologies, such as brain imaging to assess for stroke,
renal insufficiency or failure, and endocrine and neuroendocrine
pathology.
4. Multidisciplinary management
5. Intensive care unit (ICU) management
6. Consideration of intensive interventions (e.g. plasma, high dose
IV methotrexate with leucovorin rescue; monoclonal antibodies
against IL-1, IL-6, etc)
7. Ventilator support
Fig. 2. (continued).
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Future Directions

While much has been learned over the past year about the COVID-19
pandemic and the SARS-CoV-2 Coronavirus which causes it, we are
increasingly recognizing that while the lung is the principal target of the
disease, virtually any tissue or body organ can ultimately become a target
of the disease process (either via direct viral targeting, or through
secondary mechanisms whereby damage is produced by a compromise
in the necessary, constant, and high fidelity delivery of life-sustaining
oxygen-rich blood everywhere throughout the body.
A crucial area of scientific inquiry shall address the rapidly expanding
observation that subsequent to surviving COVID-19; even those with the
mildest variants of this disorder, can be predisposed to the development
of a post-COVID-19 syndrome; so-called “Long-Hauler’s” syndrome [112115].
Long-Hauler’s syndrome is characterized by a constellation of recalcitrant
symptoms, which can include chronic fatigue, alterations in cognitive
capabilities, persistent breathing problems, exercise intolerance, as well
as residual deficits in those who have suffered stroke, seizures, heart
attack, kidney and liver derangements, as well as disturbances in the
gastrointestinal tract [112-115].
We believe that the information underscored above, further support our
contention about the role of early treatment intervention, as both a
prevention and disease attenuation strategy. ‘Time is tissue’, and the
earlier we can intervene to quench the exaggerated immune network
inflammatory responses to the SARS-CoV-2 agent, the less likely our
patients are to progressively advance to severe disease, and thereby
manifest more severe morbidity, persistence of post-COVID-19
syndromes, and even death from this very serious infection [116].
Fig. 2. (continued).
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